US Stock Insider Trading | NewAmsterdam Pharma disclosed 7 insider transactions on February 26

K-LinePoet · 2026-03-26T20:04:42+00:00

On February 26, 2026, NewAmsterdam Pharma disclosed multiple insider transactions, including senior executives such as Director Davidson Michael H., who sold a significant amount of shares involving over $8 million. The company focuses on developing non-statin drugs for cardiovascular diseases, with its main candidate being obicetrapib.

K-LinePoet

2026-03-26 20:04:42

Abstract generation in progress

On February 26, 2026, NewAmsterdam Pharma (NAMS) disclosed seven insider transactions. Director Davidson Michael H. sold 165,400 shares on February 26, 2026.

【Recent Insider Transactions】

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 26, 2026	Director	Davidson Michael H.	February 25, 2026	Sell	10,400	35.96	375,300
February 26, 2026	Director	Davidson Michael H.	February 24, 2026	Sell	3,161	36.46	115,300
February 26, 2026	Director	Davidson Michael H.	February 25, 2026	Sell	1,300	36.68	47,700
February 26, 2026	Director	Davidson Michael H.	February 26, 2026	Sell	165,400	33.63	5,562,700
February 26, 2026	Director	Davidson Michael H.	February 25, 2026	Sell	46,500	35.11	1,633,200
February 26, 2026	Director	Davidson Michael H.	February 24, 2026	Sell	61,500	36.13	2,223,700
February 26, 2026	Director	Davidson Michael H.	February 26, 2026	Sell	17,900	34.44	617,300
February 24, 2026	Director	Kastelein Johannes Jacob Pieter	February 20, 2026	Sell	14,700	35.00	514,200
February 24, 2026	Director	Kastelein Johannes Jacob Pieter	February 20, 2026	Sell	30,800	35.46	1,091,800
January 29, 2026	Executive	Kooij Louise Frederika	January 28, 2026	Sell	32,600	31.80	1,037,100

【Company Information】

NewAmsterdam Pharma Company N.V. was incorporated as a private limited liability company under Dutch law on October 17, 2019, under the name NewAmsterdam Pharma B.V. In October 2021, it was renamed NewAmsterdam Pharma Holding B.V. They are a clinical-stage biopharmaceutical company developing oral non-statin drugs for high-risk cardiovascular disease (CVD) patients with elevated residual low-density lipoprotein cholesterol (LDL-C or LDL), for whom existing therapies are insufficient or poorly tolerated. As an adjunct to statins, an effective, cost-efficient, and convenient LDL-lowering therapy is in high unmet demand. Statins are the current standard of care for high-cholesterol high-risk CVD patients. Their lead candidate, obicetrapib, is a next-generation oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, currently in four Phase 3 and 2b clinical trials, as monotherapy and in combination with ezetimibe, to lower LDL-C and prevent major adverse cardiovascular events (“MACE”).

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes